IMRX Immuneering Corporation
USHealthcareAs of 2026-07-09 16:00
Why IMRX matters now
Immuneering Corporation (IMRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.36 with -3.07% on the session and $194.6M in market capitalization; recent performance reads 1-month -9.82% and YTD -32.98%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-13.5M, and EPS of $-0.21. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -31.2%.
The latest indexable market news headline is "Immuneering Appoints Andrew Gengos as Chief Financial Officer" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes Hall Brett Matthew filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
-65.30
DCF Value
$2.80
FCF Yield
-31.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-0.1%
ROA
-0.0%
ROIC
-0.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-13.5M | $-0.21 |
| Q4 2025 | $0.00 | $-11.6M | $-0.18 |
| FY 2025 | $0.00 | $-56.0M | $-1.27 |
| Q3 2025 | $0.00 | $-15.0M | $-0.38 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.38
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.